BMRN PDUFA date: FDA decision expected February 28, 2027

The FDA is expected to decide on this application from BioMarin Pharmaceutical Inc. by the PDUFA target action date of February 28, 2027. SNDA filing. Extracted from: U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia

A PDUFA date is the FDA's target deadline to complete its review of a drug application — approval, a complete response letter (CRL), or an extension are all possible. What is a PDUFA date? This page is research information, not financial advice.